Sep 10, 2026 · 37 min · 13 segments
*Disseminated on behalf of* Onco-Innovations Ltd.*, may include paid advertisements.* AUSTIN, Texas, September 10, 2026 – via…
Islam MohamedGuest
Carmel FisherHost
I'm a specialist in radiation oncology, and I serve as the chief medical officer at Onco Innovations Limited.
And then I spent over 25 years treating cancer patients and conducting clinical research.
At OncoInnovations, my responsibility is the clinical translation of our lead drug candidate, Onco10, and that's taking a compound with a substantial body of laboratory and animal evidence and carrying that into a first-in-human trial.
So in practice, that means executing the regulatory strategy, the design of the study, and preparing a scientific case that has to survive the scrutiny of a regulator.
But looking at your background, you've spent a considerable amount of time in radiation oncology.
Why the transition? What sparked the move for you, if at all, a move away from that industry?
While I did wind down my clinical practice in radiation oncology, I haven't left oncology.
And I wanted to deal with the potential failure mode of my treatments at the system level rather than one patient at a time.
So my job was to deliver radiotherapy, a DNA damaging treatment that's intended to kill cancer cells by overwhelming their ability to repair that genetic damage.
And while the treatment often works, a portion of those cancers are resistant to treatment and the cancers can return.
And I've had to share the terrible news of a cancer relapse with my patients on too many occasions.
So in late 2023, when I was asked to evaluate several prospective drug candidates in oncology, these were intellectual property on offer from technology transfer offices at Canadian universities.
I saw one that was a nanoparticle encapsulated inhibitor of a DNA repair enzyme that had never been targeted for cancer treatments before.
So here was a possible drug directed at precisely the failure mode that I had been encountering in my practice.
So on the strength of the preclinical foundation behind it, I judged that it was worth considering for commercial development.
As the program entered late preclinical evaluation, it became evident that directing clinical translation required someone full time.
I'm a specialist in radiation oncology, and I serve as the chief medical officer at Onco Innovations Limited.
And then I spent over 25 years treating cancer patients and conducting clinical research.
At OncoInnovations, my responsibility is the clinical translation of our lead drug candidate, Onco10, and that's taking a compound with a substantial body of laboratory and animal evidence and carrying that into a first-in-human trial.
So in practice, that means executing the regulatory strategy, the design of the study, and preparing a scientific case that has to survive the scrutiny of a regulator.
But looking at your background, you've spent a considerable amount of time in radiation oncology.
Why the transition? What sparked the move for you, if at all, a move away from that industry?
While I did wind down my clinical practice in radiation oncology, I haven't left oncology.
And I wanted to deal with the potential failure mode of my treatments at the system level rather than one patient at a time.
So my job was to deliver radiotherapy, a DNA damaging treatment that's intended to kill cancer cells by overwhelming their ability to repair that genetic damage.
And while the treatment often works, a portion of those cancers are resistant to treatment and the cancers can return.
And I've had to share the terrible news of a cancer relapse with my patients on too many occasions.
So in late 2023, when I was asked to evaluate several prospective drug candidates in oncology, these were intellectual property on offer from technology transfer offices at Canadian universities.
I saw one that was a nanoparticle encapsulated inhibitor of a DNA repair enzyme that had never been targeted for cancer treatments before.
So here was a possible drug directed at precisely the failure mode that I had been encountering in my practice.
So on the strength of the preclinical foundation behind it, I judged that it was worth considering for commercial development.
As the program entered late preclinical evaluation, it became evident that directing clinical translation required someone full time.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
